ALAUNOS THERAPEUTICS INC (TCRT) Fundamental Analysis & Valuation

NASDAQ:TCRT • US98973P3091

3.47 USD
-0.02 (-0.57%)
Last: Mar 11, 2026, 08:27 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TCRT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

TCRT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. The financial health of TCRT is average, but there are quite some concerns on its profitability. TCRT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. TCRT Profitability Analysis

1.1 Basic Checks

  • TCRT had negative earnings in the past year.
  • TCRT had a negative operating cash flow in the past year.
  • In the past 5 years TCRT always reported negative net income.
  • In the past 5 years TCRT always reported negative operating cash flow.
TCRT Yearly Net Income VS EBIT VS OCF VS FCFTCRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • TCRT has a worse Return On Assets (-108.08%) than 77.26% of its industry peers.
  • TCRT has a Return On Equity of -143.60%. This is in the lower half of the industry: TCRT underperforms 62.62% of its industry peers.
Industry RankSector Rank
ROA -108.08%
ROE -143.6%
ROIC N/A
ROA(3y)-217.74%
ROA(5y)-158.17%
ROE(3y)-293.94%
ROE(5y)-216.39%
ROIC(3y)N/A
ROIC(5y)N/A
TCRT Yearly ROA, ROE, ROICTCRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TCRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRT Yearly Profit, Operating, Gross MarginsTCRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K -600K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. TCRT Health Analysis

2.1 Basic Checks

  • TCRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TCRT has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TCRT has less shares outstanding
  • TCRT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCRT Yearly Shares OutstandingTCRT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
TCRT Yearly Total Debt VS Total AssetsTCRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • TCRT has an Altman-Z score of -345.26. This is a bad value and indicates that TCRT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TCRT (-345.26) is worse than 95.38% of its industry peers.
  • TCRT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -345.26
ROIC/WACCN/A
WACC8.79%
TCRT Yearly LT Debt VS Equity VS FCFTCRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • TCRT has a Current Ratio of 2.92. This indicates that TCRT is financially healthy and has no problem in meeting its short term obligations.
  • TCRT has a worse Current ratio (2.92) than 64.93% of its industry peers.
  • A Quick Ratio of 2.92 indicates that TCRT has no problem at all paying its short term obligations.
  • TCRT has a worse Quick ratio (2.92) than 63.20% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.92
TCRT Yearly Current Assets VS Current LiabilitesTCRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TCRT Growth Analysis

3.1 Past

  • The earnings per share for TCRT have decreased strongly by -14.06% in the last year.
  • Looking at the last year, TCRT shows a decrease in Revenue. The Revenue has decreased by 0.00% in the last year.
  • Measured over the past years, TCRT shows a very negative growth in Revenue. The Revenue has been decreasing by -70.71% on average per year.
EPS 1Y (TTM)-14.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.57%
Revenue 1Y (TTM)0%
Revenue growth 3Y-70.71%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • TCRT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.09% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y243.33%
EPS Next 2Y32.92%
EPS Next 3Y21.64%
EPS Next 5Y13.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TCRT Yearly Revenue VS EstimatesTCRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
TCRT Yearly EPS VS EstimatesTCRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. TCRT Valuation Analysis

4.1 Price/Earnings Ratio

  • TCRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRT Price Earnings VS Forward Price EarningsTCRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRT Per share dataTCRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • TCRT's earnings are expected to grow with 21.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.92%
EPS Next 3Y21.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TCRT Dividend Analysis

5.1 Amount

  • No dividends for TCRT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TCRT Fundamentals: All Metrics, Ratios and Statistics

ALAUNOS THERAPEUTICS INC

NASDAQ:TCRT (3/11/2026, 8:27:00 PM)

3.47

-0.02 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-30
Inst Owners6.36%
Inst Owner Change65.47%
Ins Owners4.93%
Ins Owner Change2.34%
Market Cap7.74M
Revenue(TTM)6.00K
Net Income(TTM)-4.03M
Analysts43.33
Price TargetN/A
Short Float %1.8%
Short Ratio1.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1289.68
P/FCF N/A
P/OCF N/A
P/B 2.76
P/tB 2.76
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-1.35
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -108.08%
ROE -143.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-217.74%
ROA(5y)-158.17%
ROE(3y)-293.94%
ROE(5y)-216.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -9700%
Cap/Sales 1616.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.92
Altman-Z -345.26
F-Score4
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)5.45%
Cap/Depr(5y)202.23%
Cap/Sales(3y)1315.8%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.57%
EPS Next Y243.33%
EPS Next 2Y32.92%
EPS Next 3Y21.64%
EPS Next 5Y13.09%
Revenue 1Y (TTM)0%
Revenue growth 3Y-70.71%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y45.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y90.27%
OCF growth 3YN/A
OCF growth 5YN/A

ALAUNOS THERAPEUTICS INC / TCRT FAQ

What is the ChartMill fundamental rating of ALAUNOS THERAPEUTICS INC (TCRT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TCRT.


Can you provide the valuation status for ALAUNOS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to ALAUNOS THERAPEUTICS INC (TCRT). This can be considered as Overvalued.


What is the profitability of TCRT stock?

ALAUNOS THERAPEUTICS INC (TCRT) has a profitability rating of 0 / 10.


How financially healthy is ALAUNOS THERAPEUTICS INC?

The financial health rating of ALAUNOS THERAPEUTICS INC (TCRT) is 6 / 10.